Jump to content

Drilldown: Medicines

Choose a table:


Medicines > generic: None & fda max : 10 mg/d or 150 mg/d

Use the filters below to narrow your results.

generic: (Click arrow to add another value)
brand:
Dayvigo (1) · Sunosi (1)
classes:
Dual orexin receptor antagonist (DORA) (1) · Norepinephrine-dopamine reuptake inhibitor (NDRI) (1) · wake-promoting agent (1)
mechanism:
Competitive antagonist at OX1R and OX2R. Faster receptor association/dissociation kinetics than suvorexant (~16 sec dissociation vs ~57 sec) hypothesized to support sleep onset, with sufficient duration for maintenance. (1) · Selective dopamine and norepinephrine reuptake inhibitor (DAT and NET inhibition). Unlike amphetamine, does not significantly release monoamines, pure reuptake inhibition. (1)
uses:
Excessive daytime sleepiness in adults with narcolepsy or obstructive sleep apnea (OSA) (1) · Insomnia (sleep onset and/or maintenance) in adults (FDA-approved Dec 2019) (1)
starting dose:
5 mg PO at bedtime; may increase to 10 mg if inadequate (1) · Narcolepsy: 75 mg PO once daily upon awakening, titrate every 3 days. OSA: 37.5 mg PO once daily, titrate. (1)
preparations:
5 mg, 10 mg tablets (1) · 75 mg, 150 mg tablets (1)
fda max: (Click arrow to add another value)
routes:
Oral (2)
onset:
~30 min (1) · ~30-60 min (1)
duration:
~7-8 hours (1) · ~9 hours (1)
halflife:
~17-19 hours (longer than daridorexant) (1) · ~7.1 hours (1)
bioavailability:
~44% (1) · ~95% (1)
pregnancy:
Limited data; avoid (1) · Limited data; pregnancy exposure registry available (1)
legal:
Rx, Schedule IV (US) (2)

Showing below up to 2 results in range #1 to #2.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"